Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.

CT imaging is the traditional method of tracking progression and recurrence in ovarian cancer, but Wright explains this poses several issues. Interpreted CT scan results vary amongst radiologists, which ultimately demonstrates a lack of reliability.

Traditional clinical trials have also used imaging to define recurrence in this disease. Though blood marker CA-125 is found in a great concentration of ovarian cancer cells and is likely to appear abnormal prior to a CT scan, oncologists are unsure how to use it as a marker of recurrence in ovarian cancer. 

Videos

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer. 


Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the molecular biology of ovarian cancer.

Wright says ovarian cancer tends to be a very heterogeneous disease. Because each tumor is so different, researchers are faced with the challenge of classifying each tumor into subgroups.

Once tumors can be categorized, physicians would have a better idea about who would benefit from each different targeted therapy, Wright says.

Jason D. Wright, MD

Articles

Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer

Dr. Wright Discusses the Molecular Biology of Ovarian Cancer